Literature DB >> 509834

Articular pathology of ankylosing spondylitis.

J Ball.   

Abstract

The essential articular pathology of AS may be said to reflect the occurrence, severity, and overall bias of (a) synovitis which tends to produce articular erosion, and (b) an inflammatory enthesopathy which results in capsular ossification in diarthrodial joints and syndesmophyte formation in cartilaginous joints, both of which are primarily responsible for bony ankylosis. Nonspecific secondary mechanisms contribute to the final picture. These include enchondral ossification, which produces synostosis, osteoporosis and altered stress distribution which make the axial skeleton susceptible to trivial trauma, the destructive effects of which are sometimes described as spondylodiskitis.

Entities:  

Mesh:

Year:  1979        PMID: 509834

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  4 in total

Review 1.  Advances in the understanding of entheseal inflammation.

Authors:  Dennis McGonagle; Michael Benjamin; Helena Marzo-Ortega; Paul Emery
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

2.  Progressive ankylosis (ank/ank) in mice: an animal model of spondyloarthropathy. III. Proliferative spleen cell response to T cell mitogens.

Authors:  H E Krug; M L Mahowald; C Clark
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

3.  Integrative structural biomechanical concepts of ankylosing spondylitis.

Authors:  Alfonse T Masi; Kalyani Nair; Brian J Andonian; Kristina M Prus; Joseph Kelly; Jose R Sanchez; Jacqueline Henderson
Journal:  Arthritis       Date:  2011-12-18

4.  Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS.

Authors:  Janine Bleil; Joachim Sieper; Rene Maier; Uwe Schlichting; Axel Hempfing; Uta Syrbe; Heiner Appel
Journal:  Arthritis Res Ther       Date:  2015-07-17       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.